Results 251 to 260 of about 36,256 (261)

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Nature Communications, 2022
Daniel J Renouf, Jonathan Loree, Ravi Ramjeesingh   +2 more
exaly  

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Lancet, The, 2019
Luis Paz-Ares, Katsuyuki Hotta, Oleksandr Voitko   +2 more
exaly  

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

New England Journal of Medicine, 2017
Scott J Antonia, Shuji Murakami, David Planchard   +2 more
exaly  

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Lancet Oncology, The, 2018
Marina Chiara Garassino, Johan Filip Vansteenkiste, Jesus Corral Jaime   +2 more
exaly  

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Lancet Oncology, The, 2016
Scott Antonia, Jamie E Chaft, Naiyer A Rizvi   +2 more
exaly  

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

New England Journal of Medicine, 2018
Scott J Antonia, Shuji Murakami, Takayasu Kurata   +2 more
exaly  

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

Lancet Respiratory Medicine,the, 2018
Aldo Morra, Diana Giannarelli, Alessia covre   +2 more
exaly  

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Journal of Clinical Oncology, 2016
Christophe Massard, Jason J Luke, Tyler J Curiel   +2 more
exaly  

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Lancet Oncology, The, 2019
Rina Hui, Ki Hyeong Lee, Byoung Chul Cho
exaly  

Durvalumab

Reactions Weekly, 2018
openaire   +1 more source